



Prior to publication, the information contained within this announcement was deemed by the Company to constitute inside information as stipulated under the UK Market Abuse Regulations. With the publication of this announcement, this information is now considered to be in the public domain.

21 February 2025

**Proteome Sciences plc
("Proteome Sciences" or the "Company")**

Substantial contract for Proteome Sciences

Proteome Sciences (AIM:PRM), is pleased to announce that the Company has secured a contract win from a US biopharmaceutical company using the Company's mass spectrometry services for the analysis of samples for an on-going clinical trial. This project will be provided utilising the Good Clinical Laboratory Practice ("GCLP") accreditation obtained by Proteome Sciences specifically for this type of project. The contract value is in excess of US\$1m and the Company considers that a significant proportion of the work should be completed in the current financial year and into 2026.

Commenting on the contract, Richard Dennis, Chief Commercial Officer of Proteome Sciences said:

"In April 2024 we announced the first contract from this customer and commented that we expected additional contracts to be received from them in the near future. This contract represents a further targeted assay that we will perform under GCLP compliance to monitor drug performance in an ongoing clinical trial. As in 2024 we are seeing increasing interest for GCLP work from other major biopharma clients in both the US and Europe and expect additional orders to follow in 2025."

- Ends -

For further information:

Proteome Sciences plc

Dr. Ian Pike, Chief Scientific Officer

Richard Dennis, Chief Commercial Officer

Tel: +44 (0)20 7043 2116

Allenby Capital Limited (Nominated Adviser & Broker)

John Depasquale/Lauren Wright (Corporate Finance)

Tel: +44 (0) 20 3328 5656

Tony Quirke/Stefano Aquilino (Equity Sales & Corporate Broking)

About Proteome Sciences plc. (www.proteomics.com)

Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. SysQuant® and TMT®MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator™ provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available.